Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney disease linked to faster memory loss, new study aims to find out why

NCT ID NCT04975464

Knowledge-focused Sponsor: Anne Murray Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 600 people with and without chronic kidney disease (CKD) for up to four years to compare how often memory loss, confusion, and daily activity problems occur. Researchers will also look for risk factors that make thinking and memory worse in CKD patients. Participants undergo annual memory tests, medical interviews, and some have brain scans to understand the role of kidney health in brain function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

600 people

The number who actually took part.

Started

Nov 2011

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All potential participants must be previous BRINK participants

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for CKD Participants: 1. In stages 3b-5 of chronic kidney disease (GFR ≤ 60 ± 5 ml/min/1.73m2) at the first baseline visit in BRINK 1.0. 2. Able to complete an approximately 90 minute cognitive and physical testing battery. 3. Able to sign the informed consent, or allow a caregiver, relative, surrogate, or witness to sign the informed consent if participant is unable to do so. Inclusion Criteria for non-CKD Participants: 1. GFR ≥ 60 ± 5 ml/min/1.73m2 at the first baseline visit in BRINK 1.0. 2. Able to complete an approximately 90 minute cognitive and physical testing battery. 3. Able to sign the informed consent, or allow a caregiver, relative, surrogate, and/or witness to sign the informed consent if participant is unable to do so. Exclusion Criteria: Exclusion Criteria for CKD and non-CKD Participants: 1. Acute psychiatric illness that would impede cognitive testing 2. Active chemical dependence 3. Legally blind or unable to complete cognitive tests due to visual loss or deafness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease chronic kidney disease chronic renal failure syndrome cognitive disorder Cognitive Dysfunction dementia diabetes mellitus kidney disorder stroke disorder vascular dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Cerebral atrophy Chronic kidney diseases Cognitive decline Cognitive dysfunction Cognitive impairment Dementia Dementia, vascular Diabetes Kidney diseases Small vessel ischemic disease Stroke

Contacts and locations

Locations

  • Hennepin Healthcare Research Institute

    Minneapolis, Minnesota, 55404, United States

  • Minneapolis VA Healthcare System

    Minneapolis, Minnesota, 55378, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.